S-1/A: OS Therapies Files Amendment for $15 Million Equity Line of Credit Resale

OS Therapies aims to register the resale of up to $15 million in common stock through an equity line of credit, alongside commitment shares.

Summary

• OS Therapies has filed an amendment to its Form S-1 registration statement to register the resale of up to $15 million of its common stock by Square Gate Capital Master Fund, LLC through an equity line of credit.
• The registration includes 5,597,015 shares based on a price of $2.68 per share on November 11, 2024, as well as 165,746 initial commitment shares and up to 450,000 true-up shares.
• OS Therapies will not receive any proceeds from the sale of shares by Square Gate Capital, but may receive up to $15 million in gross proceeds from the investor under the ELOC Purchase Agreement.
• The company intends to use any proceeds from the Facility to advance clinical development programs, expand discovery, research and preclinical activities and for additional general corporate purposes.
• The ELOC Purchase Agreement will remain in effect until the earlier of October 31, 2026, or the date on which the Investor has purchased the Maximum Commitment Amount.
• In December 2024, OS Therapies entered into a PIPE Financing, raising $6,050,000 before deducting transaction fees and other estimated PIPE Financing expenses.
• The PIPE Purchase Agreement requires OS Therapies to seek stockholder approval for any transactions contemplated by the PIPE Purchase Agreement and the related documents for which the rules of the NYSE American require stockholder approval and to hold a special meeting of stockholders for the purpose of obtaining Stockholder Approval not later than April 9, 2025.

Sentiment

Score: 5

Explanation: The document is primarily factual and descriptive, outlining the terms of a securities offering and related agreements. While it mentions potential risks, it also highlights the company's plans for using the proceeds, resulting in a neutral sentiment.

Positives

• The company has access to a committed equity facility of up to $15 million.
• The company intends to use any proceeds from the Facility to advance clinical development programs, expand discovery, research and preclinical activities and for additional general corporate purposes.
• The company completed a PIPE Financing in December 2024, raising $6,050,000 before deducting transaction fees and other estimated PIPE Financing expenses.

Negatives

• The company will not receive any proceeds from the resale of shares by the investor.
• The sale of a substantial number of shares could adversely affect the prevailing market price of the company's shares.
• The company's independent registered public accounting firm has expressed substantial doubt about its ability to continue as a going concern.
• The company has incurred significant operating losses in recent periods and anticipates that it will incur continued losses for the foreseeable future.

Risks

• The sale of a substantial number of ELOC Shares in the public market, as well as shares issuable in connection with the December 2024 PIPE Financing, could adversely affect the prevailing market price of the company's shares.
• It is not possible to predict the actual number of ELOC Shares, if any, the company will sell under the ELOC Purchase Agreement to the Investor, or the actual gross proceeds resulting from those sales.
• Investors who buy ELOC Shares from the Investor at different times will likely pay different prices.
• The company may use the proceeds from sales of its ELOC Shares pursuant to the ELOC Purchase Agreement in ways with which you may not agree or in ways which may not yield a significant return.
• The company is a clinical stage biopharmaceutical company and has not generated any revenue to date from drug sales, and may never become profitable.
• If the company is unable to raise capital when needed or on attractive terms, it would be forced to delay, scale back or discontinue some of its product candidate development programs or commercialization efforts.
• The company's independent registered public accounting firm has expressed substantial doubt about its ability to continue as a going concern.

Future Outlook

The company intends to use any proceeds from the Facility to advance clinical development programs, expand discovery, research and preclinical activities and for additional general corporate purposes.

Industry Context

The document mentions increased acquisition and licensing interest from large pharmaceutical firms in biotechnology companies developing antibody-drug conjugate (ADC) technology as a relatively new kind of cancer therapy.

Stakeholder Impact

• Existing stockholders may experience dilution as a result of the issuance of new shares.
• The market price of the company's shares could be affected by the sale of a substantial number of shares.
• The company's ability to execute its business plan could be enhanced by the availability of additional capital.

Next Steps

• The company will seek stockholder approval for the transactions contemplated by the PIPE Purchase Agreement.
• The company will hold a special meeting of stockholders for the purpose of obtaining Stockholder Approval not later than April 9, 2025.
• The company will use reasonable best efforts to, by no later than January 31, 2025, submit to the SEC a registration statement covering the resale of a number of shares of common stock underlying the Series A Preferred Stock and the Series A Warrants issued pursuant to the PIPE Purchase Agreement equal to 300% of the shares of common stock initially issuable thereunder, and to use commercially reasonable efforts to cause such registration statement to be declared effective by the SEC within 45 days thereafter.

Key Dates

Keywords

ELOC, Equity Line of Credit, PIPE Financing, Common Stock, OS Therapies, Resale, Shares, Investor, OSTX, Securities